| Quarterly Financials | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 1,764 | 2,200 | 2,457 | 2,130 | 2,103 | 2,642 | 2,772 | 2,682 | 2,517 | 2,976 | 3,189 | 3,286 | 3,333 | 3,653 | 3,791 |
| Expenses | 1,441 | 1,724 | 1,835 | 1,654 | 1,636 | 1,924 | 2,025 | 2,000 | 1,836 | 2,196 | 2,227 | 2,383 | 2,401 | 2,724 | 2,776 |
| EBITDA | 323 | 476 | 622 | 477 | 467 | 718 | 746 | 681 | 681 | 780 | 962 | 903 | 933 | 930 | 1,016 |
| Operating Profit % | 17 % | 21 % | 24 % | 21 % | 20 % | 25 % | 25 % | 23 % | 24 % | 23 % | 28 % | 26 % | 22 % | 24 % | 25 % |
| Depreciation | 47 | 78 | 79 | 85 | 85 | 87 | 97 | 110 | 100 | 103 | 106 | 187 | 231 | 219 | 222 |
| Interest | 13 | 16 | 10 | 13 | 5 | 6 | 9 | 9 | 9 | 11 | 7 | 221 | 191 | 171 | 170 |
| Profit Before Tax | 263 | 382 | 533 | 379 | 377 | 625 | 641 | 562 | 572 | 666 | 849 | 495 | 511 | 541 | 624 |
| Tax | 70 | 84 | 110 | 83 | 84 | 130 | 130 | 103 | 95 | 123 | 190 | 111 | 86 | 96 | 104 |
| Net Profit | 193 | 298 | 423 | 296 | 294 | 494 | 511 | 460 | 477 | 543 | 659 | 385 | 425 | 445 | 520 |
| EPS in ₹ | 4.74 | 7.30 | 10.48 | 7.09 | 7.13 | 12.15 | 12.51 | 11.33 | 11.76 | 13.39 | 16.31 | 9.46 | 10.19 | 10.62 | 12.39 |
Mankind Pharma
Mankind Pharma
2,264.00
-45.10
(-1.95%)
Company has added their latest Financial Results22 hours ago
Show All
Key Fundamentals
Market Cap
93,448.52 Cr
EPS
49.28
PE Ratio
49.83
Dividend Yield
0.00 %
Industry
Healthcare 52 Week High
3,054.80
52 Week Low
2,115.10
PB Ratio
6.65
Debt to Equity
0.37
Sector
Pharmaceuticals Analyst Rating and Forecast
- By Refinitiv from16 analysts
Actual
Company News
View All News
Mankind Pharma Limited announced its quarterly results for the quarter and half year ended September 30, 2025. The company reported revenue from operations of Rs. 2,608.78 crores for the quarter, compared to Rs. 2,261.43 crores in the previous year quarter, representing growth. Net profit for the quarter stood at Rs. 458.90 crores versus Rs. 362.68 crores in the corresponding period last year. For the six-month period, revenue reached Rs. 4,956.80 crores against Rs. 4,497.80 crores in the previous year. The company's earnings per share for the quarter was Rs. 11.10 compared to Rs. 10.00 in the prior year quarter. The Board of Directors approved these unaudited standalone and consolidated financial results at their meeting held on November 6, 2025. The company continues to face ongoing income tax proceedings initiated by the Income Tax Department under Section 132 of the Income Tax Act, 1961, with appeals currently pending with appellate tax authorities.
Mankind Pharma Targets 20%+ Revenue Growth with Export Expansion and Specialty Portfolio Focus
19 hours ago
19 hours agoMankind Pharma has outlined growth guidance targeting sustained revenue growth of over 20%, driven by chronic therapy and BSV specialty portfolio expansion. The company reported strong export performance with 82% year-over-year growth. Management expects margin improvements from specialty and super-specialty products, along with a revival in consumer healthcare. The company aims to strengthen its OTC leadership position and double export contribution over the next three years.
Mankind Pharma reported Q2 consolidated net profit of 5.11 billion rupees, down from 6.56 billion rupees in the same period last year. Revenue increased to 36.97 billion rupees compared to 30.61 billion rupees year-over-year. EBITDA rose to 9.21 billion rupees from 8.47 billion rupees, while EBITDA margin declined to 24.92% from 27.67% in the previous year.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,690.00 | #1 4,05,487.61 | 38.58 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 54.39 | |
6,667.50 | 1,77,001.18 | 79.27 | 9,712.00 | 18.67 | 2,191 | 35.10 | 74.24 | |
1,500.40 | 1,21,195.42 | 22.30 | 28,409.50 | 7.12 | 5,291 | 3.71 | 39.79 | |
3,579.50 | 1,21,146.55 | 60.08 | 11,539.40 | 6.99 | 1,911 | 19.91 | 46.89 | |
1,206.80 | 1,00,721.19 | #1 17.53 | 33,741.20 | 16.73 | 5,725 | -0.38 | 36.98 | |
941.40 | 94,726.87 | 20.00 | 23,511.00 | 18.55 | 4,615 | 34.60 | 30.29 | |
2,264.00 | #7 93,448.52 | #8 49.83 | #8 12,744.20 | #1 20.90 | #9 2,007 | #10 -21.05 | 28.96 | |
1,969.50 | 89,957.80 | 24.00 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 50.08 | |
5,654.50 | 67,608.03 | 28.92 | 13,458.30 | 3.70 | 2,216 | 21.39 | 62.15 | |
1,123.00 | 65,224.02 | 19.54 | 32,345.60 | 9.43 | 3,484 | 3.81 | 59.80 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
20.90 %
Net Income Growth
3.39 %
Cash Flow Change
12.12 %
ROE
-32.07 %
ROCE
-46.01 %
EBITDA Margin (Avg.)
5.21 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 6,373 | 9,148 | 9,715 | 11,963 | 27,760 |
| Fixed Assets | 1,664 | 3,588 | 4,251 | 4,545 | 19,005 |
| Current Assets | 3,907 | 4,407 | 4,328 | 6,568 | 6,988 |
| Capital Work in Progress | 372 | 702 | 550 | 282 | 826 |
| Investments | 1,512 | 1,110 | 1,346 | 2,568 | 2,042 |
| Other Assets | 2,824 | 3,749 | 3,568 | 4,568 | 5,887 |
| Total Liabilities | 6,373 | 9,148 | 9,715 | 11,963 | 27,760 |
| Current Liabilities | 1,353 | 2,624 | 1,863 | 2,120 | 5,664 |
| Non Current Liabilities | 156 | 208 | 229 | 268 | 7,528 |
| Total Equity | 4,863 | 6,316 | 7,623 | 9,576 | 14,568 |
| Reserve & Surplus | 4,682 | 6,115 | 7,395 | 9,323 | 14,291 |
| Share Capital | 40 | 40 | 40 | 40 | 41 |
Cash Flow
| Cash Flow | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 103 | -92 | 156 | 22 | 77 | 22 |
| Investing Activities | -436 | -1,222 | -1,369 | -1,052 | -2,081 | -12,624 |
| Operating Activities | 1,070 | 1,137 | 920 | 1,813 | 2,152 | 2,413 |
| Financing Activities | -531 | -8 | 605 | -740 | 5 | 10,233 |
Share Holding
| % Holding | Sept 2022 | Mar 2023 | May 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 79.00 % | 76.50 % | 76.50 % | 76.50 % | 76.50 % | 76.50 % | 74.88 % | 74.87 % | 74.87 % | 72.71 % | 72.70 % | 72.68 % | 72.67 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 9.87 % | 11.58 % | 12.37 % | 13.34 % | 12.92 % | 13.07 % | 12.84 % |
| DIIs | 0.00 % | 2.64 % | 2.64 % | 4.64 % | 4.39 % | 9.49 % | 11.14 % | 9.95 % | 9.90 % | 11.06 % | 11.48 % | 11.50 % | 11.92 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 4.15 % | 4.15 % | 1.02 % | 1.11 % | 1.14 % | 1.22 % | 1.46 % | 1.55 % | 1.60 % | 1.64 % | 1.52 % | 1.36 % |
| Others | 21.00 % | 16.71 % | 16.71 % | 17.83 % | 18.00 % | 12.87 % | 2.89 % | 2.15 % | 1.31 % | 1.30 % | 1.26 % | 1.23 % | 1.21 % |
| No of Share Holders | 17 | 4,02,322 | 4,02,322 | 1,31,918 | 1,34,731 | 1,27,449 | 1,35,116 | 1,53,450 | 1,63,854 | 1,72,431 | 1,80,597 | 1,79,549 | 1,70,347 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 09 Aug 2024 |  Annual General Meeting | NA | 09 Aug 2024 | 2,114.50 | 2,068.60 |
| 05 Nov 2024 |  Quarterly Result Announcement | NA | 05 Nov 2024 | 2,506.95 | 2,734.95 |
| 23 Jan 2025 | Quarterly Result Announcement | NA | 23 Jan 2025 | 2,738.25 | 2,515.05 |
| 21 May 2025 | Quarterly Result Announcement | NA | 21 May 2025 | 2,430.05 | 2,550.70 |
| 31 Jul 2025 | Quarterly Result Announcement | NA | 31 Jul 2025 | 2,578.00 | 2,575.00 |
| 07 Aug 2025 | Annual General Meeting | NA | 07 Aug 2025 | 2,386.35 | 2,553.25 |
| 08 Aug 2025 |  Dividend | ₹ 1.00 /share | 08 Aug 2025 | 2,575.00 | 2,541.90 |
| 06 Nov 2025 | Quarterly Result Announcement | NA | 06 Nov 2025 | 2,431.65 | 2,369.35 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation7 minutes ago
7 minutes agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication3 hours ago
3 hours agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome19 hours ago
19 hours agoFinancial Results For The Quarter And Half Year Ended 30Th September 202522 hours ago
22 hours agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release22 hours ago
22 hours agoAnnouncement under Regulation 30 (LODR)-Investor Presentation22 hours ago
22 hours agoBoard Meeting Outcome for Outcome Of Board Meeting22 hours ago
22 hours agoIntimation Regarding ESG Rating2 days ago
2 days agoIntimation Regarding ESG Rating8 days ago
8 days agoAnnouncement under Regulation 30 (LODR)-Credit Rating8 days ago
8 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation9 days ago
9 days agoBoard Meeting Intimation for Approval Of Financial Results For The Quarter And Half Year Ended On September 30 202510 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Updates on AcquisitionOct 10, 2025
Oct 10, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 04, 2025
Oct 04, 2025Closure of Trading WindowSep 25, 2025
Sep 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 15, 2025
Sep 15, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 10, 2025
Sep 10, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 09, 2025
Sep 09, 2025Intimation Of Receipt Of Approval For ReclassificationSep 02, 2025
Sep 02, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 27, 2025
Aug 27, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 26, 2025
Aug 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 25, 2025
Aug 25, 2025Intimation Regarding ESG RatingAug 22, 2025
Aug 22, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionAug 19, 2025
Aug 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 11, 2025
Aug 11, 2025Announcement under Regulation 30 (LODR)-Change in ManagementAug 08, 2025
Aug 08, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 08, 2025
Aug 08, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 06, 2025
Aug 06, 2025Intimation For Submission Of Application For ReclassificationAug 03, 2025
Aug 03, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 01, 2025
Aug 01, 2025Announcement Under Regulation 30- TDS Communication To The Shareholders.Jul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-RestructuringJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-AcquisitionJul 31, 2025
Jul 31, 2025Intimation Of Record DateJul 31, 2025
Jul 31, 2025Corporate Action-Board approves DividendJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJul 31, 2025
Jul 31, 2025Un-Audited Financial Results For The Quarter Ended On June 30 2025Jul 31, 2025
Jul 31, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On July 31 2025Jul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionJul 24, 2025
Jul 24, 2025Intimation Of Receipt Of Request For ReclassificationJul 22, 2025
Jul 22, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 18, 2025
Jul 18, 2025Intimation Of Dispatch Of Letter To Shareholders Whose E-Mail Addresses Are Not Registered With Company Or DepositoriesJul 17, 2025
Jul 17, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 17, 2025
Jul 17, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 15, 2025
Jul 15, 2025Reg. 34 (1) Annual Report.Jul 15, 2025
Jul 15, 2025Mutual Fund Holdings
SBI Large Cap Direct Plan-Growth 
HDFC Large Cap Fund Direct-Growth 
Axis ELSS Tax Saver Direct Plan-Growth 
Invesco India Contra Fund Direct-Growth 
PGIM India Midcap Fund Direct-Growth 
Canara Robeco Large Cap Fund Direct-Growth 
Kotak Small Cap Fund Direct-Growth 
Nippon India Pharma Fund Direct-Growth 
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth 
Edelweiss Mid Cap Direct Plan-Growth 
Sundaram Mid Cap Fund Direct-Growth 
Franklin India Opportunities Direct Fund-Growth 
Bandhan Large & Mid Cap Fund Direct-Growth 
Aditya Birla Sun Life Flexi Cap Fund Direct-Growth Technical Indicators
RSI(14)
Neutral 28.96
ATR(14)
Volatile 50.06
STOCH(9,6)
Neutral 24.55
STOCH RSI(14)
Oversold 10.29
MACD(12,26)
Bearish -8.29
ADX(14)
Weak Trend 17.75
UO(9)
Bearish 41.87
ROC(12)
Downtrend And Accelerating -6.76
WillR(14)
Oversold -98.16
About Mankind Pharma
Mankind Pharma Limited is an Indian pharmaceutical company incorporated in 1991. It develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products. The company operates in various therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. Mankind Pharma entered the consumer healthcare segment in 2007 and has since expanded into animal healthcare, female infertility treatments, and oncology. The company operates 23 manufacturing facilities across India with a total installed capacity of 40.77 billion units as of March 31, 2022. In April 2023, Mankind Pharma went public through an Initial Public Offer. The company has acquired several subsidiaries and brands, and has expanded internationally with subsidiaries in the US, Singapore, Nepal, and UAE.
Listing Date
09 May, 2023(2 Years,
-2 days)
Chairperson NameRAMESH CHAND JUNEJA
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
